Hans-Georg Wirsching
Hans-Georg Wirsching
University Hospital Zurich
Bestätigte E-Mail-Adresse bei usz.ch
Titel
Zitiert von
Zitiert von
Jahr
DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis
F Sahm, D Schrimpf, D Stichel, DTW Jones, T Hielscher, S Schefzyk, ...
The lancet oncology 18 (5), 682-694, 2017
3212017
Advances in the molecular genetics of gliomas—implications for classification and therapy
G Reifenberger, HG Wirsching, CB Knobbe-Thomsen, M Weller
Nature reviews Clinical oncology 14 (7), 434-452, 2017
2862017
MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial
M Weller, G Tabatabai, B Kästner, J Felsberg, JP Steinbach, A Wick, ...
Clinical cancer research 21 (9), 2057-2064, 2015
2252015
Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma—Results from the DIRECTOR trial
B Suchorska, M Weller, G Tabatabai, C Senft, P Hau, MC Sabel, ...
Neuro-oncology 18 (4), 549-556, 2016
1382016
Glioblastoma
HG Wirsching, E Galanis, M Weller
Handbook of clinical neurology 134, 381-397, 2016
1192016
Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery
PJ Cimino, M Zager, L McFerrin, HG Wirsching, H Bolouri, B Hentschel, ...
Acta neuropathologica communications 5 (1), 1-14, 2017
642017
Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence
LM Katz, T Hielscher, B Liechty, J Silverman, D Zagzag, R Sen, P Wu, ...
Acta neuropathologica 135 (6), 955-963, 2018
502018
Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial
HG Wirsching, G Tabatabai, U Roelcke, AF Hottinger, F Jörger, A Schmid, ...
Annals of oncology 29 (6), 1423-1430, 2018
462018
Predicting outcome of epilepsy after meningioma resection
HG Wirsching, C Morel, C Gmür, MC Neidert, CR Baumann, A Valavanis, ...
Neuro-oncology 18 (7), 1002-1010, 2016
422016
Thymosin beta 4 gene silencing decreases stemness and invasiveness in glioblastoma
HG Wirsching, S Krishnan, AM Florea, K Frei, N Krayenbühl, ...
Brain 137 (2), 433-448, 2014
332014
The role of molecular diagnostics in the management of patients with gliomas
HG Wirsching, M Weller
Current treatment options in oncology 17 (10), 1-16, 2016
282016
Mutational patterns and regulatory networks in epigenetic subgroups of meningioma
N Paramasivam, D Hübschmann, UH Toprak, N Ishaque, M Neidert, ...
Acta neuropathologica 138 (2), 295-308, 2019
252019
Copy number profiling across glioblastoma populations has implications for clinical trial design
PJ Cimino, L McFerrin, HG Wirsching, S Arora, H Bolouri, R Rabadan, ...
Neuro-oncology 20 (10), 1368-1373, 2018
202018
Increased HOXA5 expression provides a selective advantage for gain of whole chromosome 7 in IDH wild-type glioblastoma
PJ Cimino, Y Kim, HJ Wu, J Alexander, HG Wirsching, F Szulzewsky, ...
Genes & development 32 (7-8), 512-523, 2018
162018
Thymosin β4 induces folding of the developing optic tectum in the chicken (Gallus domesticus)
HG Wirsching, O Kretz, G Morosan‐Puopolo, P Chernogorova, C Theiss, ...
Journal of Comparative Neurology 520 (8), 1650-1662, 2012
162012
Anti–PD-L1 antibody direct activation of macrophages contributes to a radiation-induced abscopal response in glioblastoma
CI Ene, SA Kreuser, M Jung, H Zhang, S Arora, K White Moyes, ...
Neuro-oncology 22 (5), 639-651, 2020
112020
Plinabulin, an inhibitor of tubulin polymerization, targets KRAS signaling through disruption of endosomal recycling
PJ Cimino, L Huang, L Du, Y Wu, J Bishop, J Dalsing-Hernandez, ...
Biomedical reports 10 (4), 218-224, 2019
112019
Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma
HG Wirsching, H Zhang, F Szulzewsky, S Arora, P Grandi, PJ Cimino, ...
JCI insight 4 (13), 2019
102019
MGMT promoter methylation as a prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: First results from …
G Tabatabai, W Wick, JP Steinbach, A Wick, O Schnell, P Hau, ...
Journal of Clinical Oncology 32 (15_suppl), 2015-2015, 2014
102014
Mitotic index thresholds do not predict clinical outcome for IDH-mutant astrocytoma
RA Yoda, T Marxen, L Longo, C Ene, HG Wirsching, CD Keene, ...
Journal of Neuropathology & Experimental Neurology 78 (11), 1002-1010, 2019
92019
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20